Illinois Gov. JB Pritzker on Monday announced a $1.5 billion investment from biotherapeutics company CSL for a new plasma ...

Across the United States, plasma centers are opening in wealthier areas as more people struggle with the high cost of housing, groceries and health care.

CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art ...

After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5-billion project.  | On Monday, CSL broke ground on an ...

Australian biopharmaceutical company CSL announced Monday a major expansion at its Kankakee manufacturing facility, a move that will bring end-to-end plasma processing into the U.S.

The Kanakee project builds on the biopharma company’s efforts to increase its U.S. footprint, where it has already spent more ...

The bottom line: We cut our fair value estimate for narrow-moat CSL by 22% to $210 due to our plasma earnings downgrades.

CSL will outlay $1.5bn over the next five years in the US to grow its footprint of plasma therapy production, the latest pharma company to pour money into the country amid tariff threats.

Australian biotech giant CSL Ltd CSL.AX' reported on Tuesday a net profit rise of 13% in the first half, bolstered by strong demand and increased plasma collection at its Behring unit. The company, ...

CSL is one of three tier one plasma therapy companies who benefit from an oligopoly in this highly consolidated market. All the players are vertically integrated as plasma sourcing is the most ...

With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. But a rebound—fueled by a surge in post-pandemic collections and an $11.7 ...